Klea Pharmaceuticals Launches in Dubai with 57 Medicines and 1,611 Pharmacies
Klea Holding announces the operational start of its subsidiary Klea Pharmaceuticals in the United Arab Emirates, in partnership with Al Khayyat Investments (AKI), a regional healthcare holding company. The transfer of the initial portfolio of 57 medicines is expected to be completed by June 2026, with initial revenues anticipated in the second half of 2026.
An Operational Subsidiary Before Summer
Klea Holding, a Parisian group listed on Euronext Growth, has established Klea Pharmaceuticals with a 46% stake alongside two founders from the international pharmaceutical sector and professional investors. The new subsidiary, based in Dubai, markets a portfolio of licensed medicines in the Middle East and Africa markets.
The transfer of regulatory approvals for the initial portfolio of 57 medicines to the Emirates Drug Establishment (EDE) is to be finalized by the end of June 2026. Klea Pharmaceuticals already has the necessary registrations under the Dubai Drug Code (DDC) and the HAAD Code (Abu Dhabi), thereby accessing both public and private markets. The subsidiary has also completed its internal organization in terms of regulation, quality, supply chain, and commercial development.
Al Khayyat Investments, Major Regional Distributor
Klea Pharmaceuticals has entrusted the distribution of its portfolio to Al Khayyat Investments, an Emirati family holding founded in 1965 with the establishment of the first pharmacy chain in the United Arab Emirates (BinSina Pharmacy, which now has more than 150 establishments in the UAE and Oman). AKI stands as one of the most significant groups in the region, with a Healthcare division holding over 4% market share in the Middle East and exceeding 15% in the United Arab Emirates.
The group manages a portfolio of more than 60 pharmaceutical laboratories, employs over 12,000 staff, and operates in several Middle Eastern countries. Its model integrates logistical capabilities, regulatory excellence, and complete mastery of the cold chain. Thanks to this partnership, Klea Pharmaceuticals' distribution network already covers 1,611 pharmacies (51% of the UAE territory) and 51 private and public hospital groups.
Gradual Revenue Increase Until 2032
Klea Pharmaceuticals aims for a revenue of more than 8.5 million AED (over 2 million Euros) by 2026, reaching over 14 million AED in its first full year of operation. The ramp-up is based on geographical expansion towards other markets in the Middle East and Africa, with a target of over 200 million AED (over 50 million Euros) by 2032.
This strategy is set against a favorable regional backdrop: the pharmaceutical market in the Middle East and Africa is valued at 28.3 billion Euros and is growing at 7.8% annually, more than double that of mature markets. The United Arab Emirates, the second most dynamic market in the region with a growth of 16.5%, benefits from universal mandatory health insurance and one of the highest private coverage rates in the world (68%).
